WHOLE genome sequencing technologies show broadly comparable accuracy in detecting genetic variation, with researchers identifying subtle differences in performance depending on genomic context in new comparative study.
The study evaluated the performance of two next generation sequencing (NGS) systems used in genomics research and precision medicine. Researchers focused on how each platform performs when sequencing human tumour cell line genomes without prior DNA amplification, a method designed to reduce bias.
Platforms Show Similar Overall Accuracy, With Differences in Specific Genomic Regions
Overall, both sequencing systems produced very similar results when identifying genetic variants, suggesting that either could be used reliably for whole-genome sequencing in clinical and research settings. However, the study identified differences in performance depending on genomic region.
One system showed fewer duplicate reads and higher read quality scores, improving confidence in sequence alignment and reducing false-positive variant calls. It also showed a modest advantage in detecting some small genetic changes, particularly at lower sequencing depths.
Performance varied by DNA sequence composition. This system performed better in high GC-content regions, which are typically more challenging to sequence, but was less consistent in long GC-rich repeats. Error rates were generally more stable in repetitive regions, although specific structures such as G-quadruplex motifs could still affect accuracy.
The other sequencing system showed strong, consistent performance across most genomic contexts, with fewer region-specific variations.
Genomic Context May Influence Platform Choice in Precision Medicine
The researchers emphasised that while both platforms are highly capable for clinical and research-grade genome analysis, understanding context-dependent differences is increasingly important as sequencing moves further into precision medicine applications, where small variations in variant detection can influence biological interpretation.
Importantly, despite the observed differences, the study concluded that both technologies remain highly comparable for most variant-calling applications, reinforcing confidence in their use for large-scale genomic studies.
As whole-genome sequencing becomes more widely used in cancer research, rare disease diagnosis, and population genomics, the findings highlight the importance of selecting sequencing platforms based not only on overall accuracy, but also on their behaviour in specific genomic regions relevant to each study.
Reference
Höjer P et al. Whole-genome sequencing with AVITI and NovaSeq X Plus reveals comparable performance with contextual biases. NAR Genom Bioinform. 2026;8(2):lqag053. DOI:10.1093/nargab/lqag053.
Featured Image: uv_group on Adobe Stock
